Piperidine/piperazine derivatives

Abstract

The invention relates to a DGAT inhibitor of formula including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —O—C(═O)—; —C(═O)—C(═O)—; —NR—C(═O)—; —Z—C(═O)—; —Z—NR—C(═O)—; —C(═O)—Z—; —NR—C(═O)—Z—; —C(═S)—; —NR—C(═S)—; —Z—C(═S)—; —Z—NR—C(═S)—; —C(═S)—Z—; —NR—C(═S)—Z—; Z represents a bivalent radical selected from Calkanediyl, Calkenediyl or Calkynediyl; wherein each of said Calkanediyl, Calkenediyl or Calkynediyl may optionally be substituted; and wherein two hydrogen atoms attached to the same carbon atom in Calkanediyl may optionally be replaced by Calkanediyl; Y represents —C(═O)—NR— or —NR—C(═O)—; Rrepresents adamantanyl, Ccycloalkyl; arylor Het; Rrepresents Ccycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said Ccycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl or heterocycle may optionally be substituted; Rrepresents hydrogen, halo, Calkyl, Calkyl substituted with hydroxyl;provided that the following compounds are excluded;a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine, as a DGAT inhibitor, of said compounds.